Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

  1. Reinoso-Segura, M.
  2. Caballero-Velázquez, T.
  3. Herrera, P.
  4. Patriarca, F.
  5. Fanin, R.
  6. Bruno, B.
  7. Einsele, H.
  8. Nahi, H.
  9. Granell, M.
  10. López-Corral, L.
  11. Reguera, J.L.
  12. García-Cadenas, I.
  13. Gahrton, G.
  14. Pérez-Simón, J.A.
Journal:
Transplantation and Cellular Therapy

ISSN: 2666-6367

Year of publication: 2022

Volume: 28

Issue: 5

Pages: 258.e1-258.e8

Type: Article

DOI: 10.1016/J.JTCT.2022.01.026 GOOGLE SCHOLAR lock_openOpen access editor